Krystal Biotech, Inc. (KRYS)
NASDAQ: KRYS · Real-Time Price · USD
149.36
+5.74 (4.00%)
At close: Aug 13, 2025, 4:00 PM
149.34
-0.02 (-0.01%)
After-hours: Aug 13, 2025, 5:33 PM EDT
Krystal Biotech Employees
Krystal Biotech had 275 employees as of December 31, 2024. The number of employees increased by 46 or 20.09% compared to the previous year.
Employees
275
Change (1Y)
46
Growth (1Y)
20.09%
Revenue / Employee
$1,306,200
Profits / Employee
$533,545
Market Cap
4.32B
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
KRYS News
- 9 days ago - Krystal Biotech, Inc. (KRYS) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 19 days ago - Krystal Biotech Announces Approval of VYJUVEK® by Japan's Ministry of Health, Labour and Welfare for the Treatment of Dystrophic Epidermolysis Bullosa - GlobeNewsWire
- 20 days ago - Jeune Announces Positive Results and Significant Aesthetic Improvements from Phase 1 Study of KB304 for Moderate to Severe Wrinkles of the Décolleté - GlobeNewsWire
- 5 weeks ago - Krystal Biotech Announces First Patient Dosed in Phase 1/2 Trial of KB801 for the Treatment of Neurotrophic Keratitis - GlobeNewsWire
- 7 weeks ago - Krystal Biotech Announces First Patient Dosed in Phase 3 Clinical Trial of KB803 for the Treatment and Prevention of Corneal Abrasions in Patients with Dystrophic Epidermolysis Bullosa - GlobeNewsWire
- 3 months ago - Krystal Biotech to Present at BofA Securities 2025 Health Care Conference - GlobeNewsWire
- 3 months ago - Krystal Biotech, Inc. (KRYS) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 3 months ago - Krystal Biotech Announces European Commission Approval of VYJUVEK® for the Treatment of Dystrophic Epidermolysis Bullosa - GlobeNewsWire